2015 | First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. | Tan, Daniel Shao-Weng; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan | J. Clin. Oncol. | | | |
2022 | Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study | Tan, Daniel S W; Kim, Sang-We; Ponce Aix, Santiago; Sequist, Lecia V; Smit, Egbert F; CHIH-HSIN YANG ; Hida, Toyoaki; Toyozawa, Ryo; Felip, Enriqueta; Wolf, Juergen; Grohé, Christian; Leighl, Natasha B; Riely, Gregory; Cui, Xiaoming; Zou, Mike; Ghebremariam, Samson; O'Sullivan-Djentuh, Leslie; Belli, Riccardo; Giovannini, Monica; Kim, Dong-Wan | European journal of cancer (Oxford, England : 1990) | 4 | 4 | |